Just a few days after CDC Director Rochelle Walensky admitted that COVID vaccines cannot protect against the transmission and spread of COVID, while also acknowledging that nearly half of all COVID-positive hospital patients were admitted for reasons other than COVID, Pfizer CEO Albert Bourla is now claiming that two doses of his company’s vaccine “offers very limited protection, if any” – but that, somehow, three doses is the magic number to protect against serious illness.
Until, of course, the company develops the fourth dose, which he says they’re working on right now.
“The two-dose vaccine offers very limited protection, if any. The three dose is the booster. They offer reasonable protection against hospitalization and deaths – I think it’s pretty good – and less protection against infection," said Bourla, who, during the initial rollout of the Pfizer vaccine last March, claimed that the two-dose regimen was "100 percent effective" at preventing COVID infections in children ages 12 to 15.
“Now, we are working on a new version that will cover omicron as well. And of course, we are waiting to have the final result,” he went on.
Pfizer’s CEO says two doses of their covid vaccine offers “limited protection, if any” against omicron. But don’t worry, guys, they’ve got a new vaccine that will work better in March. That will solve it all. pic.twitter.com/tKE1I5EboF— Clay Travis (@ClayTravis) January 11, 2022
Bourla said the newest version (an omicron-specific formula that Dr. Anthony Fauci has already claimed is unnecessary) will likely be available sometime in March.
“The hope is that we will achieve something that will have way, way better protection particularly against infections, because the protection against the hospitalizations and the severe disease — it is reasonable right now, with the current vaccines as long as you are having let’s say the third dose.”
CNBC reports that “Real-world data from the United Kingdom has shown that Pfizer’s and Moderna’s vaccines are only about 10% effective at preventing symptomatic infection from omicron 20 weeks after the second dose,” while “booster shots are up to 75% effective at preventing symptomatic infection,” per one study from the U.K.’s Health Security Agency.